This study is the first to demonstrate the central role of the ERK1/2 and Nanog signaling pathway in the maintenance of stemness and radiotherapy resistance in a subset of HNSCC cells with CD44 expression. This evidence concerns the gene MAPK3 and head and neck squamous cell carcinoma.